Peptosan

Quick links to important sections

Peptosan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peptosan

What is Peptosan? Identity, Composition, and General Purpose

Property Description
Active ingredient Bismuth Subsalicylate
Form Oral Suspension, Chewable Tablets, Caplets
Pharmacological class Gastrointestinal Agent, Antidiarrheal
Common use Relief of upset stomach, non-specific diarrhea
Origin Derived inorganic-organic salt (Synthetic)

What is Peptosan and What is its Pharmacological Class?

Peptosan is a non-prescription medication primarily categorized as a multi-action antidiarrheal and gastrointestinal agent, intended to alleviate general stomach and intestinal discomfort. The drug entity is available for oral administration in various dosage forms, notably the traditional oral suspension and solid forms like chewable tablets and caplets. The function of Peptosan is to serve as a supportive remedy for common, temporary digestive disturbances, offering a targeted action against factors that cause gut irritation.


Composition and Origin of Bismuth Subsalicylate

The single active ingredient in Peptosan is Bismuth Subsalicylate (also widely known as Bismuth Salicylate), which is an inorganic-organic salt derived synthetically. This compound is chemically distinct, composed of the element Bismuth and the Salicylate component. Bismuth Subsalicylate is frequently classified within the adsorbing antidiarrheal category, based on its action against a range of acute intestinal symptoms.

While the presence of the Salicylate component links the drug's origin to the family of salicylic acid derivatives (related to the NSAID class), its medicinal action is localized within the gut, setting it apart from systemic pain relievers. The finished preparation consists of the active ingredient combined with an aqueous vehicle or a solid excipient matrix necessary for delivery.


What General Benefit Does Peptosan Provide?

Peptosan provides a general benefit through a mechanism that combines a protective coating action with a function for intestinal fluid regulation. The Bismuth element acts physically to shield irritated tissues within the digestive tract, while the compound's overall effect helps to normalize the flow of fluids and reduce excessive secretion, which supports stool formation. This profile indicates the medication is used for managing common digestive discomforts, relieving symptoms like heartburn and non-specific diarrhea.

Regulatory References

  1. DailyMed - Bismuth Subsalicylate Label

What side effects are possible with Peptosan?

Possible Side Effects and Safety Information

The official safety profile of Peptosan (Bismuth Subsalicylate) details adverse reactions according to their classification and specifies safety constraints linked to the drug's components, as documented by regulatory authorities like the FDA and NIH.


Documented Adverse Reactions and Frequencies

Side effects are generally categorized into effects localized to the gastrointestinal system and those related to systemic absorption of the salicylate component. The most frequently documented reactions are considered non-serious and temporary.

Classification System-Organ Class Specific Reaction (Regulatory Terminology)
Common Gastrointestinal Disorders Blackening of the tongue and darkening of the stool (black stool)
Rare Ear and Labyrinth Disorders Tinnitus (ringing or buzzing in the ears)

Serious Adverse Reactions and Population-Specific Constraints

The regulatory safety documents outline the potential for serious, though rare, adverse reactions, particularly with systemic exposure or in specific populations.

Serious Risks:

  • Reye's Syndrome: A severe risk linked to the salicylate component, leading to a strict contraindication for use in children and teenagers recovering from viral illnesses (e.g., flu or chickenpox).
  • Salicylism (Toxicity): Potential for systemic toxicity from the salicylate component, which can manifest as Tinnitus or other effects, especially in cases of overdosage.
  • Bismuth Encephalopathy: Rare neurotoxicity associated specifically with prolonged, high-dose therapy and accumulation of bismuth.

Safety Restrictions: Patients with renal impairment face an increased risk of systemic accumulation and toxicity of both Bismuth and Salicylate. Additionally, regulatory labeling restricts use in individuals with underlying conditions such as gastrointestinal ulcers or bleeding disorders, and those with a known salicylate allergy.

Overdose and Emergency Response

Overdose and when to seek help

Overdose information is characterized by the potential for dual-component toxicity, stemming from both the salicylate and bismuth elements of the compound.

Category Official Regulatory Statement
Documented overdose presentations Overdose is categorized by dual-component toxicity. Manifestations include signs of salicylate toxicity, such as tinnitus (ringing in the ears), confusion, hyperventilation, vomiting, and metabolic imbalances like acidosis. Chronic exposure may lead to bismuth toxicity, presenting as neurotoxicity, ataxia, and deterioration of mental status.
Life-threatening outcomes Regulator documentation specifies that overdose may result in severe or life-threatening outcomes, including convulsions (seizures), coma, non-cardiac pulmonary oedema, renal failure, and unconsciousness or death.
Emergency actions required Get emergency help at once and contact a Poison Control Center right away. Immediate medical assistance is required if the victim has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.
Management procedures Management is symptomatic and supportive. Procedures include gastric lavage and the administration of activated charcoal for acute ingestion. Haemodialysis or the use of chelating agents may be considered for severe cases.
Population-specific risks A specific warning addresses the risk of Reye's syndrome when administered to children or teenagers with viral illnesses like the flu or chickenpox. Elderly and patients with kidney disease are cited as having an increased risk of adverse effects.

This profile defines the toxicological risks from both drug components and establishes the mandatory emergency action triggers required by regulators. These mandates guide individuals to seek immediate medical help when severe clinical manifestations are observed, defining the conditions under which hospitalization and symptomatic and supportive treatment are necessary.

Therapeutic Uses of Peptosan

What Peptosan Treats: Main Uses and Benefits

Peptosan is applied across domains where additional symptomatic support is needed, primarily to help with relief in situations involving certain distressing symptoms. These therapeutic strategies are relevant for easing symptoms like pain and frequency in certain urological conditions. Peptosan is applicable for conditions where functional stability becomes affected, including those involving acute, episodic, or recurrent manifestations.

Quick Fact: Supports in managing Noticeable Physiological Strain

Its use is associated with supporting the patient during difficult episodes by easing distress and contributing to improved comfort during periods of heightened symptoms. This helps address symptom clusters that create noticeable physiological strain and helps maintain a sense of stability when symptoms are more noticeable. It is commonly used when short-term symptomatic assistance is needed to help with physical discomfort.

Regulatory References

  1. European Medicines Agency's overview of Elmiron

Eligibility and Restrictions for Use

Who can and cannot use Peptosan?

The use of Peptosan (Bismuth Subsalicylate) is subject to specific population eligibility rules defined by government health authorities. Use is generally established for adults and adolescents aged 12 years and older who do not have documented contraindications.

Peptosan is absolutely contraindicated for several groups. This includes individuals with a known allergy to salicylates (such as aspirin) or those who currently have an ulcer, a bleeding problem, or bloody/black stool. A critical restriction applies to children and teenagers recovering from chickenpox or flu-like symptoms, for whom use is prohibited due to the risk of Reye's syndrome.

For certain populations, use is conditional and requires consultation with a health professional. This applies to children under 12 years of age, and individuals who are pregnant or breastfeeding. Caution is also advised for patients with significantly impaired renal function due to the presence of the salicylate component, as well as those presenting with a fever or mucus in the stool.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Peptosan (bismuth subsalicylate) is determined by its two components, focusing on pharmacodynamic synergism and gastrointestinal absorption interference, as outlined in regulatory documentation.

Pharmacodynamic and Exposure-Altering Interactions

Co-administration with Anticoagulants (such as warfarin) or other Salicylate-containing medicinal products (like aspirin) is documented to result in an increased risk of bleeding due to the additive effects of the salicylate component. The use of Peptosan with Antidiabetic Agents may lead to a possible enhanced hypoglycemic effect.

Conversely, the bismuth component is known to cause Gastrointestinal Absorption Interference with Tetracycline Antibiotics (e.g., doxycycline), which can decrease the absorption and subsequent exposure of the antibiotic. The salicylate component may also lessen the effectiveness of Antigout Medications.

Administration Restrictions and Cautions

A mandatory timing rule is documented to mitigate absorption interference: Tetracycline Antibiotics must be separated from Peptosan administration by a specific time interval, such as a couple of hours. Regulatory labels also restrict co-administration with Alcohol due to an enhanced risk of gastrointestinal bleeding.

Population-Specific Cautions are noted for children and adolescents with chickenpox or flu-like symptoms; use is restricted due to the established association between salicylates and the risk of Reye’s syndrome. Caution is also warranted for patients with renal impairment due to the potential for accumulated salicylate side effects.

Mechanism of Action

The mechanism of action for Peptosan ( Bismuth Subsalicylate) is multimodal, exhibiting this profile through two distinct, yet complementary, components that act locally within the gastrointestinal tract.

Modulation of Intestinal Secretory Pathways

The salicylate component provides localized inhibition of Cyclooxygenase ( COX) enzyme activity in the gut mucosa, thereby reducing the synthesis of pro-secretory prostaglandins ( PGE2). By dampening this signaling cascade, the drug contributes to the modulation of excessive water secretion and electrolyte transport into the intestinal lumen.

Physical Barrier Formation and Toxin Adsorption

The bismuth component hydrolyzes to form insoluble salts that physically coat the mucosal lining, creating a protective barrier. This barrier physically interacts with the mucosal lining and reduces the localized impact of chemical and mechanical stressors, while also adsorbing and binding various lumenal stressors and toxins within the digestive tract.

Control of Intraluminal Microbial Load

The bismuth compound exerts a localized toxic and inhibitory effect on certain pathogenic microbes, achieved through direct binding and disruption of microbial cell structures. This action limits the growth and toxin production of these microbes, which contributes to the control of microbe-induced secretory pathway activation.

Dosage and Administration Information

Official Administration and Dosage Guidelines

Peptosan (Bismuth Subsalicylate) is administered solely via the oral route, with instructions defining use patterns for various dosage forms, including suspension, chewable tablets, and caplets.

Dosage and Frequency

For adults and adolescents 12 years of age and older, the standard single dose is 524 mg of Bismuth Subsalicylate, equivalent to two 262 mg tablets or the labeled dose volume of regular-strength suspension. This single dose may be repeated every 30 minutes to 1 hour as required. There is a limit permitting no more than 8 standard doses (approximately 4192 mg) within any 24-hour period.

When used for specific conditions, such as part of an H. pylori eradication regimen, the dose is typically 524 mg taken four times daily, often for a defined course of 10 to 14 days.

Administration Instructions

The medicine may be taken with or without food. Specific preparation steps apply to each form:

  • Oral Suspension: The bottle must be shaken well before measuring. Dosing should be performed using the dedicated cup or measuring device provided with the product to ensure accuracy.
  • Chewable Tablets: These must be fully chewed before swallowing.
  • Caplets/Tablets: These are to be swallowed whole with water and must not be crushed or chewed.

Use for non-specific diarrhea should not exceed 2 days without consultation. If a dose is missed, individuals should resume their normal schedule and are directed not to take a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Peptosan


Evidence for Acute, Non-Specific Diarrhea and Upset Stomach

Research has primarily focused on how Peptosan (Bismuth Subsalicylate) was studied for short-term outcomes related to physical discomfort during acute, non-specific diarrhea. This evidence comes from Randomized Controlled Trials (RCTs), where people experiencing acute, non-bloody diarrhea were observed in controlled settings. These trials examined changes in stool frequency and consistency to explore how symptoms change over time, largely in studied adult populations.

Studies reported measurements of changes in stool output and frequency compared to baseline within the initial, defined short-term evaluation period. Some trials monitored the overall duration of diarrheal illness and reported how the outcomes evolved in the studied groups compared to control groups. However, long-term effects are not fully established, as the existing evidence primarily focuses on the immediate, acute phase of illness.


Evidence for Traveler's Diarrhea

Research was evaluated in two distinct contexts: for the prevention of Traveler’s Diarrhea (TD) and for its acute management. This evidence includes RCTs and systematic reviews that included healthy adults traveling to areas considered high-risk. Treatment trials described measurements in the number of unformed stools and the time until symptoms evolved. For prevention, the studies monitored the development of TD during travel and examined whether the rate of illness reported differed in the studied groups.


Evidence as a Component of H. pylori Regimens

The agent was evaluated as one part of a multi-drug combination regimen intended to eliminate Helicobacter pylori (H. pylori) infection. The research describes the eradication success rates that were observed in adult populations with H. pylori-associated ulcers when receiving the entire four-drug regimen. The evidence does not determine whether the agent could be utilized as a standalone treatment for H. pylori infection, as it has not been studied independently for this use.


What the Research Landscape Still Needs to Clarify

The research is limited primarily by its focus on short-term, symptomatic relief; the long-term effectiveness profile for conditions characterized by fluctuating manifestations is not well-established. The evidence quality varies across studies, and many early trials had sample sizes that were modest. Furthermore, limited comparative evidence is available for many specific subgroups, meaning the research contributes to the broader evidence landscape where subgroup findings remain uncertain.

Key Studies & References

  1. BISMUTH SUBSALICYLATE 262 MG - bismuth subsalicylate tablet, chewable (DailyMed/FDA Labeling)
  2. Bismuth Subsalicylate - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Peptosan (FAQ)

Q: What happens if I miss a dose of Peptosan?

A: Official administration instructions address this situation directly. If a dose is missed, individuals are generally directed not to take a double dose to compensate. They should instead resume their normal dosing schedule at the next designated time.

Q: Can Peptosan be stopped suddenly, or does it require tapering?

A: Peptosan is officially designated for short, defined periods, such as a maximum of 2 days for non-specific diarrhea or as part of a 10 to 14-day H. pylori regimen. Official documents do not define a specific tapering requirement for discontinuing use.

Q: Does Peptosan cause weight gain or weight loss?

A: When reviewing the documented adverse reactions in the official safety profile, neither weight gain nor weight loss is listed among the commonly or rarely reported side effects.

Q: What should I watch for after starting Peptosan?

A: Users are directed to be aware of the potential for Tinnitus (ringing or buzzing in the ears), which can be a sign of systemic toxicity from the salicylate component. The official label notes that blackening of the tongue or dark stool are commonly observed, non-serious effects.

Q: How is the safety of Peptosan classified for use during pregnancy?

A: Official documents classify use during pregnancy as conditional, meaning consultation with a healthcare professional is necessary. The salicylate component is often restricted, particularly during the later stages of pregnancy, in accordance with safety guidelines.

Q: Is Peptosan generally suitable for older adults (seniors)?

A: Use is established for adults aged 12 and older. However, caution is advised for patients with significantly impaired kidney function. Caution is advised due to the potential for the salicylate component to accumulate in the body and contribute to toxicity.

Q: What happens if a person who shouldn't take Peptosan uses it anyway?

A: Using the medication when it is officially contraindicated is associated with a risk of serious adverse reactions. Examples include Reye’s syndrome (in children with viral illness), increased bleeding (in those with bleeding disorders or ulcers), or systemic toxicity (in those with kidney issues or salicylate allergy).

Q: What is the general long-term outlook for people who use Peptosan?

A: Regulatory summaries on research evidence indicate that the long-term effectiveness profile for conditions characterized by fluctuating manifestations is not well-established. The existing research focuses primarily on immediate, short-term relief for acute symptoms, and long-term data is limited.

Q: What does official drug labeling say about the maximum duration of use for Peptosan?

A: Official drug labeling defines the maximum duration of use based on the specific condition being addressed. For non-specific diarrhea, the regulatory limit is no more than 2 days without consulting a health professional. For specific treatments like H. pylori, the course is typically defined as 10 to 14 days.

Q: Is Peptosan considered a long-term or short-term treatment?

A: According to regulatory documents and available research, Peptosan is designated as a short-term treatment. Its use is described as being for acute conditions, such as short-term non-specific diarrhea.

Q: Is Peptosan the same type of drug as [Similar Drug Name]?

A: Peptosan is categorized as a multi-action Antidiarrheal and Gastrointestinal Agent. Its single active ingredient is Bismuth Subsalicylate, which is a specific type of inorganic-organic salt. This unique chemical composition and multimodal action profile differentiates it from other drug classes used for digestive relief.

Q: What makes Peptosan different from other drugs used for the same purpose?

A: Official information describes its action as multimodal, meaning it works in two distinct ways. One component (salicylate) reduces intestinal secretions, and the other component (bismuth) forms a protective coating on the gut lining while binding to toxins.

Q: Is hair loss listed as a side effect of Peptosan?

A: When reviewing the official safety profile, hair loss is not listed among the commonly or rarely documented adverse reactions.

Q: Does Peptosan affect mood or sleep?

A: Official safety documents do not list adverse reactions related to changes in mood or disturbances in sleep.

Q: Are there any known interactions between Peptosan and herbal supplements or vitamins?

A: Official documentation specifically describes interactions with prescription and non-prescription medications, such as blood thinners and certain antibiotics. However, official information does not specifically list known interactions with herbal supplements or vitamins.

Q: Is Peptosan safe for people with pre-existing kidney problems?

A: Official safety warnings advise caution for patients with significantly impaired kidney function. This is due to the potential for the salicylate component to accumulate in the system and may contribute to toxicity.

Q: Is Peptosan safe for people with pre-existing liver conditions?

A: Regulatory safety documents list constraints and risks primarily focused on kidney impairment, gastrointestinal ulcers, bleeding disorders, and salicylate allergy, without detailing specific constraints related to pre-existing liver conditions.

Q: Has Peptosan been studied in diverse patient populations?

A: Research overviews indicate that evidence is limited by a focus on studied adult populations. The regulatory body notes that the research landscape still needs to clarify evidence for many specific subgroups, meaning the diversity of studied groups is limited.

Q: Do studies suggest Peptosan works better for certain patient groups than others?

A: Official research summaries note that comparative evidence for many specific patient subgroups is limited. Therefore, studies do not currently provide established findings suggesting it works better for one specific subgroup over another.

Q: Why is my doctor asking me to get lab tests while taking Peptosan?

A: The use of Peptosan is associated with the potential for systemic accumulation, particularly in individuals with impaired kidney function, which may necessitate monitoring. Additionally, the drug may be known to interfere with the accuracy of certain lab tests, which can require temporary adjustments or additional monitoring.

Q: Can Peptosan cause problems with vision?

A: Official safety documents do not list adverse reactions related to vision problems.

Q: Is a metallic taste in the mouth an expected side effect of Peptosan?

A: The official safety profile lists blackening of the tongue as a common side effect. However, a metallic taste in the mouth is not specifically listed as one of the documented adverse reactions.

Q: Why are there warnings about Peptosan for people with heart conditions?

A: Official documentation details specific warnings for Reye's Syndrome, bleeding disorders, and kidney impairment due to the drug’s components. However, specific warnings concerning general heart conditions are not explicitly detailed in the regulatory documents.

Q: Can Peptosan be taken with food, or does it have to be on an empty stomach?

A: According to official drug information provided by sources such as MedlinePlus, the medicine may be taken with or without food.

Q: What should I do if I suspect an overdose of Peptosan?

A: An overdose increases the risk of serious conditions like Salicylism (systemic toxicity) or Bismuth Encephalopathy. If an overdose is suspected, immediate professional assistance or calling a poison control center is warranted.

Q: Are there any lifestyle changes recommended alongside taking Peptosan?

A: Official documents restrict co-administration with alcohol due to an enhanced risk of gastrointestinal bleeding. This restriction is an important lifestyle consideration while using the product.

How should Peptosan be stored and disposed of?

How to Store and Dispose of Peptosan?

The storage and disposal requirements for Peptosan (Bismuth Subsalicylate) are defined by official regulatory standards to maintain stability and ensure safety.


Storage Requirements

Peptosan must be stored at Room Temperature, generally between 15 C and 30 C (59 F and 86 F). It is required to keep the product in its original container, ensure the cap is tightly closed, and protect it from freezing, excessive heat, moisture, and direct light. All forms of the medicine must be stored out of the reach of children.


Disposal Instructions

Discard any outdated medicine or product past its expiration date. The preferred method for disposal is using an authorized drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash. Do not dispose of this medication in wastewater (e.g., flushing down the toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Peptosan found in:

A-Z Index: